title: Therapy-related myelodysplasia and fludarabine combination therapy - do the benefits justify the risk?
authors.affiliation: Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Australia. dennis.carney@petermac.org
authors.forename: Dennis A
authors.initials: DA
authors.lastname: Carney
authors.forename: John F
authors.initials: JF
authors.lastname: Seymour
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009190:Myelodysplastic Syndromes / Q000139:chemically induced*; D016609:Neoplasms, Second Primary / Q000139:chemically induced; D018570:Risk Assessment; D014740:Vidarabine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D014740:Vidarabine; C024352:fludarabine